Thymidylate Synthase as a Determinant of Pemetrexed Sensitivity in Non-Small Cell Lung Cancer

作者: K Takezawa , I Okamoto , W Okamoto , M Takeda , K Sakai

DOI: 10.1038/BJC.2011.129

关键词: CarcinomaLung cancerChemotherapyMethyltransferaseThymidylate synthasePredictive markerPemetrexedPathologyBiologyCancer researchCancer

摘要: Although a high level of thymidylate synthase (TS) expression in malignant tumours has been suggested to be related reduced sensitivity the antifolate drug pemetrexed, no direct evidence for such an association demonstrated non-small cell lung cancer (NSCLC). We have now investigated effect TS overexpression on pemetrexed NSCLC cells. established lines that stably overexpress and examined effects cytotoxicity both vitro xenograft models. further relation between tumour specimens from patients response by immunohistochemical analysis. The cells overexpressing antiproliferative was markedly compared with control inhibition DNA synthesis induction apoptosis were also greatly attenuated forced TS. Furthermore, formed TS-overexpressing nude mice resistant growth-inhibitory observed tumours. Finally, non-responding significantly higher than those responders, suggestive inverse correlation pemetrexed. A confers is thus potential predictive marker pemetrexed-based chemotherapy patients.

参考文章(21)
E A Rayl, K A Shackelford, L L Habeck, V F Patel, L G Mendelsohn, V J Chen, S B Gates, R M Schultz, M Ratnam, J R Bewley, S L Andis, W C MacKellar, D J Soose, B A Moroson, W Kohler, L S Gossett, G P Beardsley, C Shih, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Research. ,vol. 57, pp. 1116- 1123 ,(1997)
B C Pestalozzi, H F Peterson, R D Gelber, A Goldhirsch, B A Gusterson, H Trihia, J Lindtner, H Cortés-Funes, E Simmoncini, M J Byrne, R Golouh, C M Rudenstam, M Castiglione-Gertsch, C J Allegra, P G Johnston, Prognostic importance of thymidylate synthase expression in early breast cancer. Journal of Clinical Oncology. ,vol. 15, pp. 1923- 1931 ,(1997) , 10.1200/JCO.1997.15.5.1923
Takeshi Hanagiri, Hidetaka Uramoto, Hidehiko Shimokawa, Takamitsu Onitsuka, TS, DHFR and GARFT Expression in Non-squamous Cell Carcinoma of NSCLC and Malignant Pleural Mesothelioma Patients Treated with Pemetrexed Anticancer Research. ,vol. 30, pp. 4309- 4315 ,(2010)
P G Johnston, E R Fisher, H E Rockette, B Fisher, N Wolmark, J C Drake, B A Chabner, C J Allegra, The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. Journal of Clinical Oncology. ,vol. 12, pp. 2640- 2647 ,(1994) , 10.1200/JCO.1994.12.12.2640
Paolo Ceppi, Marco Volante, Silvia Saviozzi, Ida Rapa, Silvia Novello, Alberto Cambieri, Marco Lo Iacono, Susanna Cappia, Mauro Papotti, Giorgio V. Scagliotti, Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer. ,vol. 107, pp. 1589- 1596 ,(2006) , 10.1002/CNCR.22208
Peter J Ferguson, Olga Collins, Nicholas M Dean, Janice DeMoor, Chen Sha-Li, Mark D Vincent, James Koropatnick, Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. British Journal of Pharmacology. ,vol. 127, pp. 1777- 1786 ,(1999) , 10.1038/SJ.BJP.0702728
K Takezawa, I Okamoto, S Tsukioka, J Uchida, M Kiniwa, M Fukuoka, K Nakagawa, Identification of thymidylate synthase as a potential therapeutic target for lung cancer British Journal of Cancer. ,vol. 103, pp. 354- 361 ,(2010) , 10.1038/SJ.BJC.6605793
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
P. G. Johnston, K. A. Behan, C. J. Allegra, R. Mick, M. E. Dolan, M. J. Ratain, W. Recant, R. R. Weichselbaum, E. E. Vokes, E. Beckmann, Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. Journal of the National Cancer Institute. ,vol. 89, pp. 308- 313 ,(1997) , 10.1093/JNCI/89.4.308